Switching from tamoxifen to aromatase inhibitors for adjuvant endocrine therapy in postmenopausal patients with early breast cancer

« Previous Next »Cancer Treatment Reviews
Volume 36, Issue 1 , Pages 54-62, February 2010

C.J.H. van de Velde
- Leiden University Medical Center, Department of Surgery, P.O. Box 9600, 2300 RC, Leiden, The Netherlands
- Corresponding author. Tel.: +31 71 526 2309; fax: +31 71 526 6750.
S. Verma
- Sunnybrook Odette Cancer Center and Sunnybrook Health Sciences Center, University of Toronto, 2075 Bayview Avenue, Room T2 045, Toronto, Ontario, Canada M4N 3M5
- Tel.: +1 416 480 5248; fax: +1 416 480 6002.
J.G.H. van Nes
- Leiden University Medical Center, Department of Surgery, P.O. Box 9600, 2300 RC, Leiden, The Netherlands
- Tel.: +31 71 526 2309; fax: +31 71 526 6744.
C. Masterman
- ACUMED, KnowledgePoint360 Group, 2nd Floor, 6 New Bridge Street, London EC4V 6AB, United Kingdom
- Tel.: +44 20 7842 0883; fax: +44 20 7353 0623.
K.I. Pritchard
- Sunnybrook Odette Cancer Center and Sunnybrook Health Sciences Center, University of Toronto, 2075 Bayview Avenue, Room T2 045, Toronto, Ontario, Canada M4N 3M5
- Tel.: +1 416 480 4616; fax: +1 416 480 6002.